Sibylla Biotech

Sibylla Biotech is developing small molecule degraders aimed at disrupting the folding process of selected proteins by binding to folding intermediates, introducing a highly differentiated approach to the field of protein degradation that can access a range of previously undruggable targets. Sibylla Biotech confronts the complexity of drug discovery with the power of innovative methods to address unmet medical needs. Sibylla disrupts the landscape of protein degradation by applying a novel mechanism of action that interferes with protein folding, thereby inhibiting the expression of disease-related proteins. Through its protein folding simulation technology platform, Sibylla identifies relevant and previously unexplored folding intermediates for protein targets, which are currently considered non-druggable in their native states. The company is developing a proprietary pipeline of small molecule Folding Interference Degraders (FID) capable of addressing a range of therapeutic areas.